Nirmatrelvir/Ritonavir

奈玛特韦/利托那韦

Report date: 2026/02/13 20:01:31
NME

Base Information

Drug NameNirmatrelvir/Ritonavir
Drug Alias NamePF-07321332/Ritonavirニルマトレルビル・リトナビルPaxlovid瑞派乐
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSARS-CoV-2-3C-like-proteinase inhibitorsHuman immunodeficiency virus type 1 protease inhibitors
TargetsSARS-CoV-2-3C-like-proteinaseHuman immunodeficiency virus type 1 protease
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Post-Acute COVID-19 SyndromeImmunologic Deficiency Syndromes +[4] 
Global Approved IndicationsCoronavirus Disease 2019 (COVID-19)
Approved Indications in ChinaCoronavirus Disease 2019 (COVID-19)
Original Approved Country/TerritoryEU
Original Approved Date2022/01/28
Country/TerritoryCzechiaBelgiumBulgaria +[31] 
CombinationsYes NirmatrelvirRitonavir
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Fosun Pharmaceutical (Group) Co LtdCanadian Institutes Of Health Research (Cihr)Beximco Pharma +[19] 
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Post-Acute COVID-19 SyndromeImmunologic Deficiency Syndromes +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A